Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMEA, Health Canada link up

This article was originally published in The Tan Sheet

Executive Summary

The health authorities will share legislation under development, draft guidance documents and non-public safety and efficacy data on regulated products, according to an implementation plan for regulatory cooperation published April 2. The European Medicines Agency and Health Canada also call for routine communication about good manufacturing practice inspections performed outside the respective territories and will allow access to each other's GMP database information. The cooperation plan says the partnership will seek to include U.S. FDA in joint activities "to minimize duplication of effort." EMEA, FDA and Australia's Therapeutic Goods Administration have launched a pilot to share GMP inspection information (1"The Tan Sheet" Jan. 19, 2009, p. 9)

You may also be interested in...

Pilot Takes Off For Inspecting API Manufacturers By U.S., Europe, Australia

FDA and its counterparts in the European Union and Australia have divided responsibilities for inspecting specific active pharmaceutical ingredient facilities in third-country locations in the next 18 months as part of a pilot to monitor more sites

Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back

A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.

Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines

Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts